Correction
Published on 04 Nov 2024
Corrigendum: Network-based prediction of anti-cancer drug combinations
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1495634
- 642 views
Type at least 3 characters
2,865 articles
Case Report
Published on 01 Nov 2024
Case report: Treatment with ensartinib shows good response to SQSTM1-ALK fusion in lung adenocarcinoma
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1433894
- 1,150 views
- 1 citation
Original Research
Published on 01 Nov 2024
Pan-cancer analysis of CLDN18.2 shed new insights on the targeted therapy of upper gastrointestinal tract cancers
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1494131
- 3,178 views
- 1 citation
Original Research
Published on 01 Nov 2024
Enhanced tumor suppression in colorectal cancer via berberine-loaded PEG-PLGA nanoparticles
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1500731
- 2,206 views
- 2 citations
Original Research
Published on 01 Nov 2024
Transcriptome analysis revealed the genes and major pathways involved in prunetrin treated hepatocellular carcinoma cells
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1400186
- 1,141 views
Review
Published on 01 Nov 2024
Targeting programmed cell death via active ingredients from natural plants: a promising approach to cancer therapy
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1491802
- 1,758 views
- 1 citation
Original Research
Published on 30 Oct 2024
Immune-related adverse events in small-cell lung cancer patients treated with immune checkpoint inhibitors: a comprehensive analysis from the FDA adverse event reporting system
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1398667
- 1,494 views
Editorial
Published on 30 Oct 2024
Editorial: Novel anti-cancer agents targeting tumour metastasis and stemness
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1504024
- 1,008 views
Review
Published on 30 Oct 2024
The role of PIK3CA gene mutations in colorectal cancer and the selection of treatment strategies
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1494802
- 5,645 views
- 5 citations
Original Research
Published on 28 Oct 2024
Adverse event profile of albumin-bound paclitaxel: a real-world pharmacovigilance analysis
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1448144
- 2,125 views
- 1 citation
Review
Published on 25 Oct 2024
Anti-tumor mechanism of artesunate
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1483049
- 4,745 views
- 1 citation
Case Report
Published on 24 Oct 2024
The addition of PD-1 inhibitor overcame trastuzumab resistance in patients with HER2 positive, PD-L1 negative metastatic gastric cancer: Case report and review of literature
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1447140
- 1,132 views
- 1 citation
Review
Published on 24 Oct 2024
Long non-coding RNAs: regulators of autophagy and potential biomarkers in therapy resistance and urological cancers
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1442227
- 1,284 views
- 1 citation
Original Research
Published on 23 Oct 2024
Synergistic effects of anlotinib and DDP on breast cancer: targeting the VEGF/JAK2/STAT3 axis
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1494265
- 2,458 views
Original Research
Published on 23 Oct 2024
Effect of fermentation on the constituents in the branches and leaves of Taxus media and non-small cell lung cancer
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1449498
- 2,665 views
Original Research
Published on 23 Oct 2024
SPAG6 overexpression decreases the pro-apoptotic effect of daunorubicin in acute myeloid leukemia cells through the ROS/JNK MAPK axis in a GSTP1-dependent manner
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1390456
- 1,857 views